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AbStrAct
Question Oppositional defiant and conduct disorders (ODD and CD) start early and persist, incurring high individual and collective costs. To inform 
policy and practice, we therefore asked: What is the best available research evidence on preventing and treating these disorders?
Study selection and analysis We sought randomised controlled trials (RCTs) evaluating interventions addressing the prevention or treatment of 
behaviour problems in individuals aged 18 years or younger. Our criteria were tailored to identify higher-quality RCTs that were also relevant to policy 
and practice. We searched the CINAHL, ERIC, MEDLINE, PsycINFO and Web of Science databases, updating our initial searches in May 2017. Thirty-
seven RCTs met inclusion criteria—evaluating 15 prevention programmes, 8 psychosocial treatments and 5 medications. We then conducted narrative 
synthesis.
Findings For prevention, 3 notable programmes reduced behavioural diagnoses: Classroom-Centered Intervention; Good Behavior Game; and Fast 
Track. Five other programmes reduced serious behaviour symptoms such as criminal activity. Prevention benefits were long term, up to 35 years. For 
psychosocial treatment, Incredible Years reduced behavioural diagnoses. Three other interventions reduced criminal activity. Psychosocial treatment 
benefits lasted from 1 to 8 years. While 4 medications reduced post-test symptoms, all caused important adverse events.
conclusions Considerable RCT evidence favours prevention.
clinical implications Effective prevention programmes should therefore be made widely available. Effective psychosocial treatments should also be 
provided for all children with ODD/CD. But medications should be a last resort given associated adverse events and given only short-term evidence of 
benefits. Policymakers and practitioners can help children and populations by acting on these findings.
bAckground
Oppositional defiant and conduct disorders (ODD and CD) are important 
public health and children’s mental health problems. They involve severe 
and persistent patterns of disruptive behaviour that fall well outside 
expected norms and that interfere with healthy development, with CD 
being the more serious condition.1 2 These 2 mental disorders are impor-
tant, in part, because of their high prevalence. Globally, recent estimates 
suggest rates of 3.6% for ODD and 2.1% for CD.3 Disruptive behaviours 
have also long been a leading reason for referrals to children’s mental 
health services.4 As well, because these disorders typically start in child-
hood then persist into adulthood, they cause inordinate burdens.5 The 
children experience significant social and emotional impairments, with 
concomitant distress and lost human potential.6 Society also incurs 
substantial healthcare, justice, child welfare and education costs—such 
that preventing just 1 case of CD at birth may yield lifetime savings of as 
much as $3.0–5.1M, based on cost analyses across multiple sectors in 
the USA (USD, 2017 equivalency).7
From a children’s rights perspective, prevention should be the highest 
priority given that behaviour disorders have been causally associated with 
serious but avoidable adversities such as family socioeconomic disadvan-
tage and child maltreatment.6 8–10 In effect, when avoidable cases are 
allowed to develop, children are doubly disadvantaged, experiencing both 
the causes and consequences of behaviour disorders.11 Many prevention 
programmes for ODD/CD have also been shown to be cost-effective.12 
Yet programmes for the prevention of these disorders—or of their under-
lying causal conditions such as child maltreatment—have yet to become 
widespread.13–15
Exacerbating the burdens, there are also acute shortages of children’s 
mental health treatment services. Even in high-income countries such as 
the UK, USA and Canada, as many as 70% of young people with mental 
disorders do not receive needed specialised treatment services.16 This 
is despite substantial (and growing) annual health expenditures in these 
jurisdictions.17–19 Globally, the situation is much worse. Many low-in-
come countries have yet to place children’s mental health on the public 
policy agenda, and mental health service shortfalls in these countries 
reach or exceed 90%.20–22 Amid these shortfalls, one approach neverthe-
less appears to be thriving, at least in high-income countries—the use of 
pharmacological treatments. For example, psychotropic prescriptions for 
children have increased approximately twofold in the UK and three-to-
fourfold in Canada in recent decades, particularly for antipsychotics which 
are increasingly being used to treat behaviour disorders.23–26
To begin to address the shortfalls and imbalances, policymakers need 
robust research evidence to guide public spending priorities. In parallel, 
practitioners need robust research evidence to inform the implementa-
tion of more effective programmes and services for children.
objective
To inform policy and practice, we therefore asked: what is the best 
available research evidence on preventing and treating ODD and CD? 
To provide comprehensive information, we included the full intervention 
continuum: prevention programmes, psychosocial treatments and phar-
macological treatments. We were aware of only 1 such previous compre-
hensive review of ODD/CD interventions, Connor et al (2006),27 which 
covered studies published from 1980 to 2005. We specifically built on this 
review, covering older studies (published from 1965 onwards) as well as 
newer studies (published from 2005 through 2017). We also expanded 
on previous reviews that examined only prevention (eg, Waddell et al, 
2007),28 only treatment (eg, National Collaborating Centre for Mental 
Health, 2013)29 or only specific types of interventions (eg, Woolfenden et 
al, 2002; Barlow et al, 2011; Sanders et al, 2014; Bakker et al, 2017).30–33 
To our knowledge, no recent systematic review has covered this compre-
hensive range of ODD/CD interventions.
Study Selection And AnAlySiS
We first searched the CINAHL, ERIC, MEDLINE and PsycINFO databases 
using the terms: conduct disorder, oppositional defiant disorder, child 
behaviour disorder, aggressive behaviour OR juvenile delinquency AND 
prevention, intervention OR treatment. To identify additional studies, we 
searched the journal, Evidence-Based Mental Health, and searched the 
Cochrane and Campbell Collaboration databases, identifying relevant 
copyright.
 o
n
 5 February 2019 by Charlotte W
addell. Protected by
http://ebm
h.bmj.com/
Evid Based M
ental Health: first published as 10.1136/eb-2017-102862 on 27 April 2018. Downloaded from
 
46  Evid Based Mental Health May 2018 Vol 21 No 2
S
ys
te
m
at
ic
 r
ev
ie
w
systematic reviews that we then hand-searched. We applied limiters, 
seeking only randomised controlled trials (RCTs) evaluating interven-
tions addressing the prevention or treatment of behaviour problems 
in individuals aged 18 years or younger. We limited our searches to 
English-language articles due to most research being published in this 
language and due to translation capacity not being available within the 
team. We also chose to seek articles published over the past 50 years 
(January 1965 through May 2017, which was the time of the last search 
update) to ensure comprehensiveness while also ensuring complete 
coverage of important databases such as MEDLINE and ERIC, which 
began in 1966. Following these searches, after screening the titles, 2 
authors independently assessed all relevant abstracts to identify eligible 
RCTs. Subsequently, 2 authors independently assessed all retrieved arti-
cles, identifying RCTs that met all the inclusion criteria. We then identi-
fied supplemental publications on these RCTs by searching the Web of 
Science database using intervention names, author names and article 
titles. This added search yielded new follow-up data from the previously 
identified RCTs as well as new RCTs that were assessed using the proce-
dures noted above. Table 1 shows the inclusion criteria. Figure 1 shows 
the search process.
We took several steps to maximise quality and minimise risk of 
bias. To ensure high-quality evaluations, only RCTs were included. Our 
inclusion criteria also specified additional quality indicators, namely 
blinding of at least 1 informant source for psychosocial studies and 
double-blinding for medication studies. To minimise risk of bias, 2 or more 
authors independently verified search results, screened abstracts and 
assessed retrieved articles. At each step, disagreements were resolved 
by consensus. Data extraction, verification, analysis and interpretations 
were also performed using consensus. To maximise policy and practice 
applicability, we focused on studies conducted in high-income countries, 
given that low-income countries have yet to be able to mobilise children’s 
mental health services on any large scale.20–22 This approach yielded 37 
RCTs (described in 165 articles) that met inclusion criteria—reporting on 
15 prevention programmes, 8 psychosocial treatments and 5 pharmaco-
logical treatments. We then assessed the risk of bias for each of these 37 
RCTs using the Cochrane risk-of-bias tool.34
Due to heterogeneity in both participants and interventions in the 
included studies, a meta-analysis was not conducted. Rather, we struc-
tured a narrative synthesis according to intervention types and outcomes. 
Interventions were first categorised as prevention programmes, psycho-
social treatments or pharmacological treatments. Behaviour findings 
pertaining to ODD/CD were then extracted, including long-term outcomes 
for related adult conditions such as antisocial personality disorder (ASPD). 
Diagnostic findings were extracted for all follow-up periods. Symptom 
findings were extracted for the longest available follow-up period or for 
2 follow-up periods when needed to meet the criterion of reporting on 2 
or more behaviour symptoms (including 1 that was blinded). (This latter 
step allowed us to include a broader range of interventions of relevance 
to policy and practice, while still ensuring rigour.)
Next, we evaluated the overall quality of the findings. We deemed 
interventions ‘notable’ if RCTs showed significant reductions in rates of 
childhood ODD/CD and/or adult ASPD diagnoses, given that diagnostic 
outcomes are a particularly robust indicator of effectiveness. We also 
noted effect sizes, where available, for both diagnostic and behaviour 
symptom outcomes. Meanwhile, we deemed adverse events associated 
with medications to be ‘important’ if they included any of the following 
symptoms: neurological (dizziness, nausea, vomiting, dystonia, drooling, 
tremor, headache or diplopia); gastrointestinal (abdominal pain); cardio-
vascular (tachycardia); endocrine (increased prolactin levels); genitouri-
nary (excessive thirst or excessive urination) and psychiatric (sedation, 
fatigue, irritability, restlessness or anxiety). This review was registered 
table 1 Randomised controlled trial inclusion criteria*
1 Children ≤18 years of age were the main focus or were clearly reported 
on separately if part of an adult study.
2 Interventions addressed childhood behaviour problems, including ODD 
and/or CD.
a. For prevention, at enrolment/pretest, <50% had a primary ODD/CD 
diagnosis or had been referred for treatment for behaviour problems or 
had been arrested.
b. For treatment, at enrolment/pretest, ≥50% had a primary ODD/CD 
diagnosis or had been referred for treatment for behaviour problems or 
had been arrested.
3 Clear descriptions were provided of participant characteristics, study 
settings and interventions.
4 Participants (or clusters) were randomly assigned to intervention and 
either control (no-intervention) or comparison (treatment-as-usual) 
groups at study outset.
5 Behaviour indicators included either one diagnostic measure where the 
diagnostician was blinded, or two symptom measures evaluated by two 
or more informant sources, eg, child, parent or teacher, at least one of 
whom was blinded.
6 Outcome measures pertained to ODD/CD, eg, scales had established 
reliability and validity or ≥50% of items addressed ODD/CD symptoms.
7 Maximum attrition was 20% at post-test (medication studies) or at 
follow-up (prevention or psychosocial treatment studies) or authors used 
intention-to-treat analyses.
8 For prevention and psychosocial treatment studies, postintervention 
follow-up was 3 months or more.
9 For medication studies, double-blinding and placebo controls were used, 
and side effects were comprehensively assessed.
10 Statistical significance (using p<0.05) was reported for relevant 
outcome measures at post-test (medication studies) or at follow-up 
(prevention and psychosocial treatment studies).
11 Interventions were evaluated in high-income countries (by World Bank 
standards).
12 Studies were not limited to specialised populations, such as children 
residing in abused women’s shelters, to retain broad applicability to 
children at risk of or who have ODD/CD.
*For inclusion, all criteria had to be met.
CD, conduct disorder; ODD, oppositional defiant disorder.
Figure 1 Search process adapted from CONSORT flow diagram.47  
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with PROSPERO (registration number CRD42016052643; see www. crd. 
york. ac. uk/ PROSPERO/).
FindingS
Prevention programmes
Sixteen RCTs met inclusion criteria, evaluating 15 different prevention 
programmes.w48-w75 Incredible Years was evaluated in 3 RCTs, while the 
Positive Parenting Program (Triple P) was evaluated in 2 RCTs. As well, 2 
RCTs evaluated 2 different programmes: Classroom-Centered Intervention 
and Family School Partnership, each assessed independently; and Triple 
P and Promoting Alternative Thinking Strategies (PATHS), each assessed 
both independently and in combination. Most programmes included 
parent training. Many also focused on developing children’s social skills 
and/or their academic skills. All programmes were delivered in commu-
nity settings such as homes, preschools and schools. Three interventions 
were delivered universally, while 12 were delivered to children at risk or 
their parents. Intervention duration ranged widely—from 1 month to 10 
years.
Thirteen of 15 prevention programmes succeeded in significantly 
reducing diagnoses or symptoms or both. Three programmes were 
notable for significantly reducing childhood CD or adult ASPD diagnoses: 
Good Behavior Game (ASPD diagnoses);w48 Classroom-Centered Interven-
tion (which included Good Behavior Game; CD diagnoses, OR=0.42);w54 
and Fast Track (ASPD diagnoses, OR=0.60).w63
As well, 5 programmes significantly reduced particularly serious 
behaviour symptoms, namely engagement in criminal activities, arrests 
or days incarcerated. These programmes included: Coping Power (crim-
inal activities, Cohen’s d [d]=0.27);w57 Fast Track (convictions/diversions 
for violent and substance-related crimes);w63 Nurse-Family Partnership 
(arrests, convictions and probation violations and adjudications as a being 
in need of supervision);w70 Parent Management Training–Oregon (arrests, 
d=0.28 and younger age at first arrest);w71 and Perry Preschool (arrests, 
OR=0.54 and months sentenced to prison, OR=0.48).w72
Six additional programmes significantly reduced at least 1 behaviour 
symptom. These included: Chicago Parent Program (behaviour prob-
lems);w55 Family Check-Up (behaviour problems);w60 Family School 
Partnership (behaviour problems, d=0.29 and school suspensions, 
OR=0.59);w53–w54 Incredible Years Basic (behaviour problems, 
d=0.63 and 0.89)w65 and coupled with Incredible Years Enhanced 
(aggression);w67 Research-Based Developmentally Informed (REDI) 
program (behaviour problems, d=0.25);w74 and Triple P I (behaviour 
problems)w49 and II (behaviour problems and aggression, d=0.11 and 
0.15, respectively).w51 Only 2 interventions failed to show any behaviour 
benefits at relevant follow-up: Montreal Prevention Programw68-w69 and 
PATHS.w51 Table 2 summarises the 15 programmes and their evaluations.
Reported effect sizes varied, as noted above. For reductions in diag-
noses, these ranged from OR=0.42 (for Classroom-Centered Interven-
tion) to OR=0.60 (for Fast Track). For reductions in criminal behaviours, 
these ranged from d=0.27 (for Coping Power) to OR=0.48 (for Perry 
Preschool). Effect sizes for reductions in general behaviour symptoms, 
meanwhile, ranged from d=0.11 (for Triple P II) to d=0.89 (for Incred-
ible Years Basic). These numbers suggest modest-to-moderately robust 
effects overall. Adverse events were not reported for any of the included 
prevention programmes.
Psychosocial treatments
Thirteen RCTs met inclusion criteria, evaluating 8 different psychoso-
cial treatments.w76–w93 All included parents in at least 1 version of the 
intervention. Five also intervened directly with children, eg, providing 
cognitive-behavioural therapy or social skills training. Some also provided 
family therapy. Treatments were delivered in clinics as well as homes, 
schools and other community settings. One intervention involved placing 
youth in specialised foster homes. Interventions were relatively short—
ranging from 2 weeks to 7 months.
Five of 8 psychosocial treatments significantly reduced diagnoses or 
symptoms or both. One treatment—Incredible Years—was notable for 
significantly reducing ODD diagnoses. Incredible Years Basic reduced ODD 
diagnoses at 7.8 year (final) follow-up (OR=0.20).w77 Incredible Years 
Basic Plus Literacy also reduced ODD diagnoses at 4-month follow-up 
(OR=0.30);w79 however, by 5.8-year (final) follow-up, this outcome was 
no longer statistically significant.w77 Three programmes stood out for 
significantly reducing particularly serious behaviour symptoms, namely 
engagement in criminal activities or days incarcerated. These treatments 
included: Brief Intervention–Youth Only (arrests);w76 Multidimensional 
Treatment Foster Care I (violent offences)w80 and II (days incarcerat-
ed);w82 and Multisystemic Therapy II (criminal activities, OR=0.41)w84 
and IV (property offences, d=0.37).w87 One other programme, Parent-
Child Interaction Therapy, reduced 1 (non-criminal) symptom (behaviour 
problems, d=0.61–0.64).w90 The remaining 3 programmes—Parent 
Management Training–Oregon, Protocol for Onsite Nurse-Administered 
Intervention and Strongest Families—failed to produce positive behaviour 
outcomes at relevant follow-up.w91–w93 Table 3 summarises the 8 psycho-
social treatments and their evaluations.
Reported effect sizes varied, as noted above. For reductions in 
diagnoses, effect size was OR=0.20 (for Incredible Years Basic). For 
reductions in criminal behaviour, effect sizes ranged from d=0.37 (for 
Multisystemic Therapy IV) to OR=0.41 (for Multisystemic Therapy II). 
The one programme that reduced general behaviour symptoms had 
effect sizes of d=0.61–0.64 (for Parent-Child Interaction Therapy). These 
numbers suggest modest-to-moderately robust effects overall. Adverse 
events were not reported for any of the included psychosocial treatments.
Pharmacological treatments
Eight RCTs met inclusion criteria, evaluating 5 different medications: 
3 antipsychotics (haloperidol, quetiapine and risperidone), 1 antiepi-
leptic (carbamazepine) and 1 mood stabiliser (lithium).w94–w101 RCTs 
were conducted in inpatient and outpatient settings. All RCTs assessed 
outcomes at post-test but not beyond, and assessed symptoms but not 
diagnoses.
All pharmacological treatments succeeded in reducing child behaviour 
symptoms with the exception of carbamazepine. Two RCTs also provided 
data on effect sizes, showing large benefits. Specifically, lithium signifi-
cantly reduced the odds of children experiencing behaviour symptoms 
(OR=9.3)w97 while quetiapine significantly reduced symptom severity 
(d=1.6).w98 However, adverse events were reported for most children 
across all the RCTs—100% of children in some cases. As well, important 
adverse events were noted for at least 50% of intervention children in 
at least 1 RCT for all medications. These problems included: dizziness 
(carbamazepine);w94 sedation and dystonia (haloperidol);w95 nausea, 
vomiting, excessive thirst and excessive urination (lithium);w97 irritability, 
restlessness, agitation, anxiety and sedation (quetiapine);w98 and fatigue 
and sedation(risperidone).w99 w101 Table 4 summarises the 5 pharmaco-
logical treatments and their evaluations.
risk of bias in included studies
Applying the Cochrane risk-of-bias assessment tool,34 we identified the 
following indicators of risk for our included RCTs. For prevention studies, 
selection bias was unclear for most; performance bias was high for all; 
detection bias was low for most; and attrition and reporting biases were 
low for all. For psychosocial treatment studies, selection bias was unclear 
for most; performance bias was high for all; detection bias was high for 
most and attrition and reporting biases were low for all. For medication 
studies, meanwhile, selection bias was unclear for most, while perfor-
mance, detection, attrition and reporting biases were low for all. The 
overall risk-of-bias profile was therefore more favourable for medication 
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compared with psychosocial studies. Nevertheless, even though many 
outcome measures for the prevention and psychosocial treatment RCTs 
were not blinded, a further audit found that more of the blinded outcomes 
were statistically significant than the non-blinded (42.9% vs 31.5%, 
respectively), suggesting that the lack of blinding did not create a bias 
favouring these types of interventions. Please see the online supplemen-
tary appendix for risk-of-bias assessments for individual RCTs.
concluSion And clinicAl imPlicAtionS
Childhood ODD and CD incur high individual and collective costs, in part 
because effective prevention and psychosocial treatment interventions 
are not made widely available. Conducted to encourage improvements in 
policy and practice, this systematic review identified 37 RCTs evaluating 
15 prevention programmes, 8 psychosocial treatments and 5 pharmaco-
logical treatments. For prevention, 3 programmes reduced behavioural 
diagnoses (Classroom-Centered Intervention; Good Behavior Game and 
Fast Track) while 5 programmes reduced serious behaviour symptoms 
such as criminal activity (Coping Power; Fast Track; Nurse-Family Part-
nership, Parent Management Training–Oregon and Perry Preschool). 
Prevention benefits were long term, up to 35 years. For psychosocial 
treatment, 1 intervention reduced behavioural diagnoses (Incredible 
Years) while 3 interventions reduced criminal activity (Brief Intervention; 
table 2 Prevention programme descriptions and evaluation findings
Programme
Sample size
(country)
Ages/grades at
programme start
(risk factors)
Programme
elements
(settings)
Programme
duration
Follow-up
after post-test
child
behaviour outcomes*
Universal programmes
  Good Behavior Gamew48 922 (USA) Grade 1
(not applicable)
Child BT
(school)
2 school years 14 years ↓ ASPD diagnoses
  Triple P Iw49–w50 280 
(Germany)
3–6 years
(not applicable)
Parent training
(community)
1 month 3.9 years ↓ 2 of 8 symptoms
11 months • 1 of 1 symptom
  Triple P II alone 1675
(Switzerland)
Grade 1—Triple P II
(not applicable)
Parent training
(community)
1 month 8 years ↓ 2 of 7 symptoms†
  PATHS alone Grade 2—PATHS
(not applicable)
Child SST
(school)
1 school year 7 years • 7 of 7 symptoms†
  Triple P II+PATHSw51–w52 As above As above As above 7 years • 7 of 7 symptoms†
Targeted programmes
  Classroom-Centered 
Intervention‡
653 (USA) Grade 1
(low income)
Child enriched curriculum, child SST+child BT
(school)
1 school year 5–11 years§ ↓ 1 of 1 symptom
5 years ↓ CD diagnoses
↓ 2 of 2 symptoms
  Family School 
Partnershipw53-w54
Parent training+parent-school collaboration (school) 5–11 years§ ↓ 1 of 1 symptom
5 years • CD diagnoses
↓ 2 of 2 symptoms
  Chicago Parent 
Programw55
504 (USA) 2–4 years
(low income)
Parent training
(community)
2.8 months 1 year ↓ 2 of 4 symptoms
  Coping Powerw56–w58¶ 245 (USA) Grade 5
(behaviour problems)
Parent training+child CBT
(school)
2 school years 3.5 years ↓ 1 of 1 symptom
1 year ↓ 1 of 1 symptom**
  Family Check-Upw59–w62 731 (USA) 2 years (behaviour problems,
maternal challenges +/or low SES)
Parent training
(home)
4.3 years 4.2 years • 1 of 1 symptom
2.2 years ↓ 1 of 1 symptom
  Fast Trackw63–w64†† 891 (USA) Grade 1
(behaviour problems)
Parent training, child SST+child tutoring
(school, community, home)
10 school years 8 years ↓ ASPD diagnoses
↓ 2 of 5 symptoms**
2 years • ODD/CD diagnoses
Incredible Years Basicw65 153 (UK) 3–4 years
(behaviour problems)
Parent training
(community)
2.8 months 3.2 months ↓ 2 of 4 symptoms
Incredible Years
Basic+Literacyw66
174 (UK) 5–6 years
(low income)
Parent training+child literacy training
(community)
4.1 months 7.9 months • 4 of 4 symptoms
Incredible 
Years Enhancedw67
92 (USA) 2–5 years
(sibling in justice system)
Parent training
(community, home)
9–11 months 8 months ↓ 1 of 2 symptoms
Montreal Prevention 
Programw68 w69
250 (Canada) Grade 2
(boys with behaviour problems)
Child SST, child BT, parent training+teacher training 
(school, home)
2 school years 19 years • 1 of 1 symptom
15 years • 1 of 1 symptom
Nurse-Family Partnershipw70 400 (USA) Prenatal
(low income, first-time mothers)
Parent training
(home)
26 months
(average)
13 years ↓ 3 of 14 symptoms**
Parent-Management 
Training—Oregonw71
238 (USA) 6–10 years
(boys living with recently separated 
mothers)
Parent training
(community)
3.2 months 8.7 years ↓ 3 of 3 symptoms**
Perry Preschoolw72 128 (USA) 3–4 years
(low income+low IQ)
Child enriched curriculum+parent-school collaboration 
(community, home)
16 months 35 years ↓ 2 of 9 symptoms**
REDIw73–w75†† 356 (USA) 4 years
(low income)
Child SST, child literacy training+teacher 
training (community)
4 months 4 years • 1 of 1 symptom
1 year ↓ 2 of 2 symptoms
↓ denotes statistically significant reductions in diagnoses/symptoms; • denotes no significant differences between intervention and control groups. 
* Diagnostic findings extracted for all follow-up periods and symptom findings extracted for either longest follow-up period or for two follow-up periods when needed to meet criterion of reporting on 2 or more behaviour 
symptoms (including one that was blinded).
 †Outcome measure completed by teachers during earlier follow-up was blinded so assumed later blinding as well. 
 ‡Good Behavior Game included in Classroom-Centered Intervention.
 §Analysis included follow-up ranging from 5 to 11 years. 
 ¶Of 245 children, 123 also received a universal intervention (Coping with Middle School Transitions); outcomes only reported for Coping Power (targeted) because it alone met criteria.
 **Reductions included particularly serious symptoms such as criminal activities, arrests, days incarcerated. 
††PATHS included in both Fast Track and REDI. 
ASPD, antisocial personality disorder; BT, behaviour training; CBT, cognitive-behavioural training; CD, conduct disorder; ODD, oppositional defiant disorder; PATHS, Promoting Alternative Thinking Strategies; REDI, Research-
Based Developmentally Informed; SES, socioeconomic status; SST, social skills training.
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Multidimensional Treatment Foster Care and Multisystemic Therapy). 
Psychosocial treatment benefits lasted from 1 to 8 years. Meanwhile, 4 
medications, mainly antipsychotics, reduced post-test symptoms, yet all 
caused important adverse events.
We believe that this review makes a unique contribution to informing 
policy and practice by covering a comprehensive array of options for chil-
dren—spanning both prevention and treatment, spanning both psycho-
social and pharmacological interventions, and spanning developmental 
stages from prenatal through adolescence. By presenting this ‘big 
picture’, we hope to encourage policymakers and practitioners to imple-
ment effective interventions and to encourage them to consider the full 
array of options, thereby interrupting the planning and service fragmen-
tation and gaps that can arise when only prevention or only treatment 
or only specific intervention types or only selected ages are considered. 
Our review also specifically updates a previous comprehensive review 
of ODD/CD interventions27 by covering a wider range of search years, 
encompassing studies that are both older and newer. We also believe 
that we have complemented previous reviews that had more narrow foci 
such as examining only prevention;28 only treatment29 or only specific 
intervention types.30–33
Yet our review has limitations. We only reported on outcomes directly 
pertaining to ODD/CD. However, several prevention programmes showed 
other important benefits including: reducing child maltreatment (Nurse-
Family Partnership);35 reducing child suicidal ideation (Good Behavior 
Game)36 and improving adult employment (Perry Preschool).37 Likewise, 
some psychosocial treatments showed other benefits such as reducing 
substance use (Multisystemic Therapy)38 and reducing attention-deficit 
symptoms (Strongest Families).39 Another limitation pertains to the lack 
of attention in the prevention and psychosocial treatment studies to 
the issue of possible adverse effects. For example, interventions such 
as Nurse-Family Partnership entail greater family scrutiny, which may 
lead to adverse effects (from the family’s perspective) such as addi-
tional child protection reporting; likewise, targeted programmes entail 
identifying children at risk, which may lead to potential stigma. Future 
prevention and psychosocial treatment research should attend to these 
issues. Our inclusion criteria for blinding also differed between psycho-
social and medication studies, which may introduce bias favouring 
psychosocial studies. We took this approach to allow us to include a 
reasonable number of psychosocial intervention studies, where double 
blinding (and placebo controls) may not be feasible. As well, we required 
table 3 Psychosocial treatment descriptions and evaluation findings 
Programme
Sample size
(country)
Ages at 
programme
start
Programme
elements
(settings)
treatment
duration
Follow-up after 
post-test
child behaviour 
outcomes*
Brief Intervention— Youth only 300 (USA) 11–17 years Child CBT
(home)
2 weeks 2 years ↓ 1 of 1 symptom†
1.5 years • 2 of 2 symptoms
Brief Intervention— 
Youth+Parentw76
Child CBT+Parent training
(home)
3 weeks 2 years • 1 of 1 symptom
1.5 years • 2 of 2 symptoms
Incredible Years Basicw77–w78 120 (UK) 3–7 years Parent training
(clinic)
3–3.7 months 7.8 years (average) ↓ ODD diagnoses
↓ 1 of 3 symptoms
Incredible Years
Basic+Literacyw77–w79
112 (UK) 4–6 years Parent training+child literacy training 
(community, home)
6.4 months 5.8 years
(average)
• ODD diagnoses
• 3 of 3 symptoms
4 months ↓ ODD diagnoses
Multidimensional Treatment 
Foster Care Iw80–w81‡
79 (USA) 12–17 years 
(boys only)
Parent training, child SST, family therapy
(home, community)
6.8 months (average) 1.4 years
(average)
↓ 2 of 2 symptoms† 
Multidimensional Treatment 
Foster Care IIw82‡
81 (USA) 13–17 years
(girls only)
Parent training, child SST, family therapy
(home, community)
5.7 months (average) 1.4 years
(average)
↓ 1 of 3 symptoms† 
Multisystemic Therapy Iw83‡,§ 118 (USA) 12–17 years Parent training, child CBT, family therapy
(home, community)
4.3 months (average) 6 months • 2 of 2 symptoms
Multisystemic Therapy IIw84‡ 131 (USA) 11–17 years Parent training, child CBT, family therapy
(home, community)
7 months
(average)
1.4 years
(average)
↓ 1 of 2 symptoms† 
Multisystemic Therapy 
IIIw85–w86
164 (USA) 11–18 years Parent training, child CBT, family therapy
(home, community+school)
5.2 months
(average)
2 years • 2 of 2 symptoms
1 year ↓ 2 of 4 symptoms
Multisystemic Therapy 
IVw87–w89
256 
(Netherlands)
12–18 years Parent training, child CBT, family therapy
(home, community)
5.7 months (average) 2.8 years
(average)
• 1 of 1 symptom
7.2 months
(average)
↓ 5 of 6 symptoms† 
Parent-Child Interaction 
Therapyw90
81 (Norway) 2–7 years Parent training
(clinic)
4.9 months
(average)
1.1 years
(average)
↓ 2 of 5 symptoms
Parent Management Training–
Oregonw91
112 (Norway) 4–12 years Parent training
(community)
6.1 months (average) 1.1 years
(average)
• 7 of 7 symptoms
Protocol for On-Site Nurse-
Administered Interventionw92
163 (USA) 6–11 years Parent training, child CBT, family therapy
(clinic)
4 months (average) 1 year • ODD/CD diagnoses
• 1 of 1 symptom
Strongest Familiesw93¶ 80 (Canada) 3–7 years Parent training¶
(home)
3.2 months 5.2 months • ODD diagnoses
↓denotes statistically significant reductions in diagnoses/symptoms; •denotes no significant differences between intervention and control groups.
*Diagnostic findings extracted for all follow-up periods and symptom findings extracted for either longest follow-up period or for 2 follow-up periods when needed to meet criterion of 
reporting on two or more behaviour symptoms (including one that was blinded).
 †Reductions included particularly serious behaviour symptoms, including criminal activities, arrests and days incarcerated. 
 ‡All youth had prior justice system involvement. 
 §All youth also met diagnostic criteria for a substance use disorder. 
 ¶Intervention predominately self-delivered using handbooks and videos supplemented with weekly telephone coaching.
 CD, conduct disorder; CBT, cognitive-behavioural training; ODD, oppositional defiant disorder; SST, social skills training. 
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that psychosocial interventions have follow-up after post-test of at least 
3 months, while only requiring post-test follow-up for medications. Still, 
risk-of-bias assessment for all included studies nevertheless confirmed 
more favourable profiles for medication compared with psychosocial 
studies, as acknowledged in the findings. Yet another limitation may arise 
from setting high thresholds for study inclusion. As a result, we do not 
discuss myriad interventions where we did not find RCT evaluations even 
though these interventions are likely being used—including some that 
may be ineffective. That said, we hope that our approach may serve as a 
pragmatic model for policymakers and practitioners. Namely, when inter-
ventions are lacking RCT evidence of effectiveness, they should only be 
used if there is a commitment to evaluating outcomes to ascertain the 
benefits for children.
Based on this review, the case for prevention appears to be particu-
larly strong—with 13 programmes showing positive findings, many at 
long-term follow-up. Most successful programmes focused on children at 
risk, suggesting that targeted approaches may be particularly beneficial 
in ameliorating early adversities, arguably even constituting a form of 
‘proportionate universalism’.40 Many, furthermore, focused on the early 
years, suggesting greater benefits with ‘upstream’ approaches. Parent 
training was also a central feature of many successful programmes, 
suggesting that supporting parents is crucial.
Beyond positive child outcomes, US cost analyses have also been 
favourable for several effective prevention programmes, suggesting that 
they may pay for themselves. These US evaluations have factored in 
intervention costs as well as estimates of reduced additional service 
use across multiple sectors over 10–15 years or more—including crim-
inal justice, social services, education and healthcare. Net benefits per 
participant have been suggested for: Good Behavior Game (US$10 800, 
2017 equivalency); Nurse-Family Partnership (US$5 100, 2017 equiv-
alency) and Parent Management Training–Oregon (US$5 700, 2017 
equivalency).12 Fast Track was also estimated to be cost-effective but 
only for the highest-risk children.41 For Perry Preschool, meanwhile, US 
estimates have suggested returns of 6–13 dollars for every programme 
table 4 Pharmacological treatment descriptions and evaluation findings
medication
(daily dose)*
Sample size
(country)
Ages at post-
test
duration
(setting)
child behaviour 
outcomes
child
adverse
events†
Carbamazepine
(400–800 mg)w94
24
(USA)
5–11 years 6 weeks
(hospital)
• 5 of 5 symptoms Weight gain 77%; dizziness 54%; headache 46%; 
leucopenia 46%; rash 46%; diplopia 38%; drowsiness 31%; 
nausea 31%; left study due to adverse events 8%
Haloperidol
(1–12 mg)
64
(USA)
5–12 years 4 weeks
(hospital)
↓ 5 of 6 symptoms‡ Any adverse event 100%; sedation 80%; dystonia 50%; 
drooling 30%; tremor 25%; left study due to adverse events 
not reported
Lithium
(500–2000 mg)w95
↓ 5 of 6 symptoms‡ Any adverse event 81%; weight gain not reported§; 
abdominal pain 33%; headache 29%; left study due to 
adverse events not reported
Lithium
(600–2100 mg)w96
55
(USA)
5–12 years 6 weeks
(hospital)
↓ 3 of 6 symptoms Weight gain 76%; vomiting 48%; abdominal pain 32%; 
tremor 28%; left study due to adverse events not reported
Lithium
(900–2100 mg)w97
40
(USA)
9–17 years 4 weeks
(hospital)
↓ 3 of 3 symptoms Weight gain 85%; nausea 60%; excessive thirst 60%; 
urinary frequency 55%¶; vomiting 55%¶; abdominal pain 
35%; headache 30%; tremor 25%; left study due to adverse 
events 0%
Quetiapine
(200–600 mg)w98
19
(USA)
12–17 years 6 weeks
(clinic)
↓ 2 of 4 symptoms Irritability 78%; restlessness 78%; agitation 67%; anxiety 
67%; sedation 67%; pacing 44%; social withdrawal 44%; 
reduced energy 33%; reduced alertness 33%; weight gain 
33%; tachycardia not reported¶; left study due to adverse 
events 11%
Risperidone**
(1.5–4 mg)w99
38
(Netherlands)
12–18 years†† 6 weeks
(hospital)
↓ 1 of 3 symptoms Fatigue 58%; physical slowing 26%; problems swallowing 
or talking 21%¶ ; increased prolactin levels not reported*; 
weight gain not reported¶; left study due to adverse events 
0%
Risperidone
(0.75–1.5 mg)w100
20
(USA)
6–14 years 10 weeks
(clinic)
↓ 5 of 6 symptoms Any side effect 80%; weight gain not reported¶; increased 
appetite 30%; sedation 30%; left study due to adverse 
events 10%
Risperidone**
(1.2 mg)‡‡w101 
119
(USA)
5–12 years†† 6 weeks
(clinic)
↓ 3 of 3 symptoms Any side effect 98%; sedation 51%¶; headache 29%; 
weight gain 15%¶; increased prolactin levels 13%¶ §§; left 
study due to adverse events 4%
 • denotes no significant differences between intervention and placebo control groups; ↓ statistically significant reductions in symptoms.
 *Reported doses include widest range that children received; dosing is not equivalent across medications. 
 †Adverse events only reported where ≥25% of children were affected or where significantly more children on medication versus placebo were affected; not all studies assessed 
whether medication and placebo adverse events differed significantly. 
 ‡In addition to both lithium and haloperidol showing significant symptom reductions over placebo on 5 of 6 measures, lithium showed significant benefits over haloperidol on 1 
symptom measure. 
 §While authors did not report proportion of children experiencing weight gain, they noted that it was considerable (ranging from means of 31.7–35.0 kg).
 ¶Adverse events experienced by significantly more children on medication than placebo. 
 **All children had below-average IQs. 
 ††Ages reflect children eligible for the study. 
 ‡‡Average daily dose; range not reported. 
 §§Significantly more boys (but not girls) experienced increased prolactin levels on medication versus placebo. 
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dollar invested.42 Estimates will vary according to countries and methods 
used; such estimates may nevertheless be helpful in encouraging more 
widespread adoption of effective prevention programmes.
Yet even if effective prevention programmes are made widely avail-
able, they could not avert all new ODD or CD cases. Treatment will always 
be needed. According to this review, Incredible Years was notable for 
reducing ODD diagnoses, while Brief Intervention, Multidimensional Treat-
ment Foster Care and Multisystemic Therapy reduced criminal activity. 
Psychosocial treatment benefits lasted from 1 to 8 years—considerable 
time in the life of a child. US cost analyses were also favourable for one 
effective programme: Multidimensional Treatment Foster Care. Factoring 
in programme costs as well as estimated lifetime reductions in the use of 
additional criminal justice, social, education and healthcare services, net 
benefits per participant have been suggested (US$9 400, 2017 equiva-
lency).12 (Costs analyses were also available for Incredible Years but none 
exclusively focused on the RCTs we reviewed.) Yet with only 5 psychoso-
cial treatments showing effectiveness, new research is needed to delin-
eate more options. We also concur with previous reviewers who have 
noted the modest effect sizes for most psychosocial treatments for ODD/
CD, especially when treatments begin when children are older33—such 
that more research is warranted, particularly with younger age groups.
In comparison, in the medication studies we reviewed, child bene-
fits were short-term and frequently associated with important adverse 
events. Some of these adverse events were fairly rare and could likely be 
managed clinically. Yet these findings are still concerning given well-doc-
umented overprescribing to children23–26—in a context where effective 
prevention programmes and psychosocial treatments are not widely 
available.16 43 As well, prescriptions for behaviour problems have often 
involved ‘off label’ use—raising additional risks for children.44 The lack of 
long-term follow-up studies on these medications is a further cause for 
concern given the evidence amassing on cardiovascular, cognitive and 
other harms associated with the long-term use of antipsychotics such 
as risperidone and quetiapine in children.26 45 More research is there-
fore needed on pharmacological treatments for childhood ODD/CD, better 
delineating long-term risks and benefits.
On balance, most of the research evidence that we identified favours 
prevention. Yet substantial hurdles need to be overcome to implement 
this evidence. Foremost, in many wealthy countries, most health spending 
goes towards providing healthcare after problems are established. In the 
UK and Canada, for example, only approximately 5% of overall health 
spending is allocated to public health including prevention.17 19 Policy-
makers will need to take concerted leadership to shift these spending 
patterns, even by modest amounts. Yet some countries are excelling at 
improving children’s mental health services, showing that the shortfalls 
and imbalances can be addressed. Australia, for example, has doubled the 
proportion of children with mental disorders who are receiving services—
from one-third in 1998 to two-thirds in 2014—by making significant new 
prevention and treatment investments.46 Beyond this, many prevention 
programmes require cross-sectoral collaboration for effective implemen-
tation. For instance, Classroom-Centered Intervention, Good Behavior 
Game and Fast Track were delivered in schools, involving teachers, while 
Nurse-Family Partnership was delivered in homes, involving public-health 
nurses. So novel collaborations among children’s mental health agencies, 
public health agencies, schools and others will need to be established 
and sustained where these do not exist.
Making prevention a priority while ensuring the availability of effective 
treatments will also require concerted efforts from practitioner groups. 
Physicians—and their professional regulatory bodies—could take lead-
ership in addressing medication overprescribing. Physicians as well as 
other practitioner groups including psychologists, social workers, nurses, 
teachers, child protection workers and school counsellors could engage 
in promoting effective prevention and psychosocial interventions for ODD/
CD. All practitioner groups could also take leadership in embracing inter-
vention models that move the children’s mental health field away from 
focussing only on individual approaches, reaching just one child at a time, 
towards also reaching many more children through population-level inter-
ventions, such as the effective prevention programmes highlighted here. 
Policymakers can assist with these efforts by funding effective interven-
tions and by supporting practitioners to provide these.
Considerable RCT evidence favours prevention, according to this review. 
Effective prevention programmes should therefore be made widely avail-
able. Effective psychosocial treatments should also be provided for all 
children with ODD/CD. But medications should be a last resort given asso-
ciated adverse events and only short-term evidence of benefits. While 
more research is needed, particularly on psychosocial interventions and 
on medications, policymakers and practitioners can nevertheless help 
children by acting on these findings now. Yet the aim is not to favour only 
prevention programmes, but rather, to achieve a balance of public invest-
ments—in effective interventions across the prevention and treatment 
continuum, so that all children in need are reached. The well-being of 
children and of populations is in the balance.
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